SCHEMBL1924312

SCHEMBL1924312

FC(F)(F)c1ccc(-c2cc(C(F)(F)F)n3cnc(-c4cccnc4)c3n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 2/20 0.43
S1PR1 P21453 1/20 0.43
NPC1 O15118 2/20 0.43
TOP1 P11387 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PIM1 P11309 1/20 0.40
DGAT1 O75907 1/20 0.40
KCNH2 Q12809 1/20 0.40
PSD A5PKW4 1/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
HTR2B P41595 1/20 0.40
HTR6 P50406 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
MET P08581 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
EPHX2 P34913 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925115 0.91 PIM1 (0.47) NPY5RNPC1SMN1; SMN2PIM1HTR2B
SCHEMBL1924686 0.90 PSD (0.50) NPY5RNPC1SMN1; SMN2PSDMAPT
SCHEMBL1924870 0.87 KIF11 (0.44) TOP1PSDMETMAPT
SCHEMBL1924986 0.84 TP53 (0.46) S1PR1SMN1; SMN2PSDMAPT
SCHEMBL1925499 0.84 TP53 (0.43) SMN1; SMN2PSDPTGS1PTGS2MAPT
SCHEMBL1925737 0.84 PSD (0.42) NPC1SMN1; SMN2PSDCYP11B1CYP11B2
SCHEMBL1924537 0.83 GAA (0.43) NPC1SMN1; SMN2PSDPTGS1PTGS2
SCHEMBL1925218 0.82 NPC1 (0.44) NPC1RAB9AEPHX2
SCHEMBL1924866 0.80 NPC1 (0.38) NPY5RNPC1SMN1; SMN2PIM1PSD
SCHEMBL1348966 0.80 GRM5 (0.45) NPY5RS1PR1NPC1TOP1PSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670801-B1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-7514443-B2 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors HOFFMANN-LA ROCHE INC. (US) 2009-04-07 US disclosed
US-20080051421-A1 Pyrazolo-pyridine WICHMANN JUERGEN 2008-02-28 US disclosed
US-7329662-B2 Pyrazolo-pyridine HOFFMANN-LA ROCHE INC. (US) 2008-02-12 US disclosed
US-20050130992-A1 Pyrazolo-pyridine F. HOFFMANN-LA ROCHE AG (CH) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130992-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR NPY5R 188/4885S1PR1 967/4885NPC1 1277/4885
US-20080051421-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR NPY5R 188/4885S1PR1 967/4885NPC1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.